References
- Berthelot J. M., Glemarec J. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford), 2002, 41: 703–5.
- Cunnane G., Warnock M. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum, 2002, 47: 445–9.
- Matsumoto Y. The rheumatoid vasculitis and malignant rheumatoid arthritis. Nippon Rinsho, 2002, 60: 2408–16.
- Lipsky P. E., Van der Heijde D. M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000, 343 :1594–602.
- Den Broeder A. A., Van den Hoogen F. H. Isolated digital vas-culitis in a patient rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. Ann Rheum Dis, 2001, 60: 538–9.
- Bartolucci P., Ramanoelina J. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford), 2002, 41: 1126–32.
- Antoni C., Braun J. Side-effects of anti-TNF therapy: current knowledge.Clin Exp Rheumatol, 2002, 20: S152–7.
- Shakoor N., Michalska M. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002, 359: 579–80.
- Galari N. A., Werth V. P. Leukoclastic vasculitis due to etanercept. J Rheumatol, 2000, 27: 2041–4.
- St. Clair E. W., Wagner C. L. The relationship of serum inflix-imab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomize, doubleblind, placebo-controlled trial. Arthritis Rheum, 2002, 46 :1451–9.